Literature DB >> 26320264

The role of T cells in the microenvironment of Hodgkin lymphoma.

Frederik Wein1, Ralf Küppers2.   

Abstract

The cellular microenvironment in HL is dominated by a mixed infiltrate of inflammatory cells with typically only 1 or a few percent of HRS tumor cells. HRS cells orchestrate this infiltrate by the secretion of a multitude of chemokines. T cells are usually the largest population of cells in the HL tissue, encompassing Th cells, T(regs), and CTLs. Th cells and T(regs) presumably provide essential survival signals for the HRS cells, and the T(regs) also play an important role in rescuing HRS cells from an attack by CTLs and NK cells. The interference with this complex interplay of HRS cells with other immune cells in the microenvironment may provide novel strategies for targeted immunotherapies. © Society for Leukocyte Biology.

Entities:  

Keywords:  chemokines; hematology; immune evasion

Mesh：

Year:  2015        PMID： 26320264      PMCID： PMC4673485          DOI： 10.1189/jlb.3MR0315-136R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


  82 in total

1.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

Authors:  Maher K Gandhi; Eleanore Lambley; Jaikumar Duraiswamy; Ujjwal Dua; Corey Smith; Suzanne Elliott; Devinder Gill; Paula Marlton; John Seymour; Rajiv Khanna
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

2.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.

Authors:  Christoph Renné; Jose Ignacio Martin-Subero; Maren Eickernjäger; Martin-Leo Hansmann; Ralf Küppers; Reiner Siebert; Andreas Bräuninger
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Immunobiology and pathophysiology of Hodgkin lymphomas.

Authors:  Sibrand Poppema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

4.  Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.

Authors:  Robert J Biggar; Elaine S Jaffe; James J Goedert; Anil Chaturvedi; Ruth Pfeiffer; Eric A Engels
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

5.  Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting.

Authors:  Jonathan R Fromm; Steven J Kussick; Brent L Wood
Journal:  Am J Clin Pathol       Date:  2006-11       Impact factor: 2.493

6.  Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).

Authors:  Scott J Rodig; Jeremy S Abramson; Geraldine S Pinkus; Steven P Treon; David M Dorfman; Henry Y Dong; Margaret A Shipp; Jeffery L Kutok
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

7.  Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

Authors:  April Chiu; Weifeng Xu; Bing He; Stacey R Dillon; Jane A Gross; Eric Sievers; Xugang Qiao; Paul Santini; Elizabeth Hyjek; Joong-won Lee; Ethel Cesarman; Amy Chadburn; Daniel M Knowles; Andrea Cerutti
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

8.  Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma.

Authors:  Jens M Chemnitz; Julia Driesen; Sabine Classen; James L Riley; Svenja Debey; Marc Beyer; Alexey Popov; Thomas Zander; Joachim L Schultze
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

9.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.

Authors:  Takashi Ishida; Toshihiko Ishii; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

10.  Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

Authors:  Holger Nückel; Ulrich H Frey; Alexander Röth; Ulrich Dührsen; Winfried Siffert
Journal:  Eur J Pharmacol       Date:  2005-05-09       Impact factor: 4.432
View more
  19 in total

1.  Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Authors:  Fathima Zumla Cader; Ron C J Schackmann; Xihao Hu; Kirsty Wienand; Robert Redd; Bjoern Chapuy; Jing Ouyang; Nicole Paul; Evisa Gjini; Mikel Lipschitz; Philippe Armand; David Wu; Jonathan R Fromm; Donna Neuberg; X Shirley Liu; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2018-06-07       Impact factor: 22.113

2.  CD83 in Hodgkin lymphoma.

Authors:  Ralf Küppers
Journal:  Haematologica       Date:  2018-04       Impact factor: 9.941

3.  Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.

Authors:  D Wang; Y Fløisand; C V Myklebust; S Bürgler; A Parente-Ribes; P O Hofgaard; B Bogen; K Taskén; G E Tjønnfjord; F Schjesvold; J Dalgaard; A Tveita; L A Munthe
Journal:  Leukemia       Date:  2017-02-24       Impact factor: 11.528

4.  Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.

Authors:  Alexej Ballhausen; Amin Ben Hamza; Carlotta Welters; Kerstin Dietze; Lars Bullinger; Hans-Peter Rahn; Sylvia Hartmann; Martin-Leo Hansmann; Leo Hansmann
Journal:  Cancer Immunol Immunother       Date:  2022-08-10       Impact factor: 6.630

Review 5.  Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.

Authors:  Taishi Takahara; Akira Satou; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Diagnostics (Basel)       Date:  2022-06-20

6.  PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.

Authors:  Masaharu Kawashima; Joaquim Carreras; Hiroshi Higuchi; Ryutaro Kotaki; Takahiro Hoshina; Kazuki Okuyama; Naoto Suzuki; Masatoshi Kakizaki; Yuji Miyatake; Kiyoshi Ando; Masafumi Nakayama; Shinjiro Umezu; Ryouichi Horie; Yuriko Higuchi; Koko Katagiri; Susumu Goyama; Toshio Kitamura; Kenji Chamoto; Shingo Yano; Naoya Nakamura; Ai Kotani
Journal:  Leukemia       Date:  2020-02-24       Impact factor: 11.528

Review 7.  Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.

Authors:  Christoph Renner; Frank Stenner
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

Review 8.  Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.

Authors:  Eleonora Calabretta; Francesco d'Amore; Carmelo Carlo-Stella
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

9.  EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.

Authors:  Chunrong Li; James C Romero-Masters; Shane Huebner; Makoto Ohashi; Mitchell Hayes; Jillian A Bristol; Scott E Nelson; Mark R Eichelberg; Nicholas Van Sciver; Erik A Ranheim; Rona S Scott; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2020-06-15       Impact factor: 6.823

10.  Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.

Authors:  Ya-Ping Zhang; Run Zhang; Hua-Yuan Zhu; Li Wang; Yu-Jie Wu; Jin-Hua Liang; Wen-Yu Shi; Hong Liu; Wei Xu; Jian-Yong Li
Journal:  Cancer Res Treat       Date:  2018-05-14       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.